Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

worldwide distribution from Lilly throughout 2024. Having discussed the main drivers of our revenue and the impact of market nuances on our quarterly performance, I want to pivot the discussion towards our pipeline and regulatory affairs concerning our proprietary, biosimilar, and complex generic products, starting with our insulin ASPART filings. We firmly believe our BLA application aimed at securing interchangeable status will not only mark a significant advancement for our diabetes portfolio, but will also demonstrate our commitment to leveraging our robust U.S.-based capabilities. This strategic move is poised to solidify our position as a frontrunner in being a proud U.S.-finished interchangeable biosimilar insulin manufacturer and supplier. This aspect sets us apart in an increasingly competitive landscape, as the demand for more affordable options for diabetic patients continues to surge we are poised to meet this need with our U.S. manufacturing site. Furthermore, we believe this milestone will pave the way for success of our other insulin products currently in development, including AMP004M, or insulin aspartame, AMP005, recombinant human insulin, and AMP025, insulin degladec, which development continues to advance. Additionally, while on the topic of our diabetes pipeline, Our GLP-1 ANDA in development, known as AMP-018, remains on track for a filing this year. In reference to our proprietary product, intranasal epinephrine, or AMP-019, this product continues to progress through the various development stages. Concluding my remarks and looking ahead, AMPA-STAR has significant opportunities in front of us. Supported by our sustained growth and strategic initiatives, With the eminent launches of Rextovi and promising candidates like Terra Paratide, AMP002, a...